Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT06166329
Recruiting Not applicable

Interest of the Chair Lift Test in the Prognostic Evaluation of Pulmonary Embolism: a Single-center Open Prospective Study

NCT06166329 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2024-02-09
Last updated
2026-02-17

Condition(s) studied

Non-severe Pulmonary EmbolismPulmonary EmbolismNon-high-risk Pulmonary EmbolismPulmonary Embolism AcutePrognostic StratificationRisk Assessment in Pulmonary EmbolismFunctional Exercise TestingEarly Prognostic Evaluation

Investigational drug(s) / intervention(s)

chair lift test

chair lift test: repetitions of the sit-stand position at a self-timed speed (safe and comfortable) as many times as possible for 1 minute

Study summary

The objective of the study is to evaluate the prognostic performance of the chair lift test in the initial assessment of the severity of non-severe pulmonary embolism in hospitalized patients, in comparison with the current pulmonary embolism risk stratification score using the sPESI score refined by the use of cardiac biomarkers and right ventricular dysfunction

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Diagnosis of pulmonary embolism according to clinical algorithm, confirmed by thoracic angioscan or ventilation perfusion (V/P) scan, * Non-serious pulmonary embolism, not requiring intensive care (thrombectomy or fibrinolysis not considered). * sPESI score ≥ 1 \[or = 0 with elevated troponin or presence of markers of VD dysfunction, or = 0 with need for hospitalization due to comorbidities unrelated to PE (social isolation, comprehension disorders, intercurrent infection, chronic renal failure, advanced cancer...) * Patients with no contraindications to chair lift testing (no O2 at the time of testing). * Effective anticoagulation for at least 1 hour. Exclusion Criteria: * sPESI score = 0 with outpatient referral. * Diagnostic confirmation of Pulmonia Embolism by thoracic angioscan or scintigraphy more than 24h after suspicion of diagnosis. * Hospitalization \> 24h after introduction of anticoagulation, with subsequent confirmation by scintigraphy. * Any sign of serious Pulmonia Embolism, requiring hospitalization in an intensive care unit. * Asymptomatic Pulmonia Embolism discovered by chance

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Chu Rouen Rouen France Recruiting

More University Hospital, Rouen trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06166329 on ClinicalTrials.gov ↗ ← All trials in France